Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The differentiation state of small intestinal organoid models influences prediction of drug-induced toxicity

ABSTRACT: The differentiation state of small intestinal organoid models influences prediction of drug-induced toxicity

PROVIDER: PRJNA1162903 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30726703_1.fastq.gz	Fastqsanger.gz
	SRR30726703_2.fastq.gz	Fastqsanger.gz
	SRR30726704_1.fastq.gz	Fastqsanger.gz
	SRR30726704_2.fastq.gz	Fastqsanger.gz
	SRR30726705_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

The differentiation state of small intestinal organoid models influences prediction of drug-induced toxicity

Project description:Drug-induced intestinal toxicity (GIT) is a frequent dose-limiting adverse event that can impact patient compliance and treatment outcomes. In vivo, there are proliferative and differentiated cell types critical to maintaining intestinal homeostasis. Traditional in vitro models using transformed cell lines do not capture this cellular complexity, and often fail to predict intestinal toxicity. Primary tissue-derived intestinal organoids, on the other hand, are a scalable Complex in vitro Model (CIVM) that recapitulates major intestinal cell lineages and function. Intestinal organoid toxicity assays have been shown to correlate with clinical incidence of drug-induced diarrhea, however existing studies do not consider how differentiation state of the organoids impact assay readouts and predictivity. We employed distinct proliferative and differentiated organoid models of the small intestine to assess whether differentiation state alone can alter toxicity responses to small molecule compounds in cell viability assays. In doing so, we identified several examples of small molecules which elicit differential toxicity in proliferative and differentiated organoid models. This proof of concept highlights the need to consider which cell types are present in CIVMs, their differentiation state, and how this alters interpretation of toxicity assays.

2025-01-23 | GSE277613 | GEO

Drug Combination Signatures for Prediction and Mitigation of Toxicity.

Project description:Drug Combination Signatures for Prediction and Mitigation of Toxicity.

| PRJNA731502 | ENA

Drug Combination Signatures for Prediction and Mitigation of Toxicity

Project description:Drug Combination Signatures for Prediction and Mitigation of Toxicity

| PRJNA657744 | ENA

Drug Combination Signatures for Prediction and Mitigation of Toxicity [single cell]

Project description:Drug Combination Signatures for Prediction and Mitigation of Toxicity [single cell]

| PRJNA733493 | ENA

Copper toxicity response influences mesotrophic Synechococcus community structure

Project description:Copper toxicity response influences mesotrophic Synechococcus community structure

| PRJNA350850 | ENA

Sunitinib efficacy with minimal toxicity in patient-derived organoid models of retinoblastoma

Project description:Background. Recurrence or persistence of retinoblastoma (RB) is common following chemoreduction and often be managed with intra-arterial/ intravitreal chemotherapy. However, no/minimal response to local chemotherapy has been documented, with enucleation needed for tumor control. Otherwise, the globe is preserved with effective tumor control but at the cost of vision due to retinal toxicity. The aim of this study was to discover novel drug with improved antitumor activity and retinal safety profiles for RB via drug reprofiling in patient-derived tumor organoids. Methods. Five tumor organoid lines were fully characterized using CGH/SNP array and whole exome sequencing and used as a model to test 133 FDA-approved compounds using two-step screening processes. RNA sequencing was conducted to generate drug signature in conjunction with cell cycle and apoptotic assays. An ability of candidate drug to restrict proliferative tumor cone were examined together with retinal toxicity testing in human ESC-derived retinal organoids, in comparison with clinically used drugs by immunostaining. Results. Sunitinib was identified as high cytotoxic agent for the classical RB1-deficient and novel MYCN-amplified RBs. Gene signature indicated that anti-tumoral activity of sunitinib was associated with MAPK activity. Additionally, sunitinib was more effective to suppress proliferative tumor cones and had less retinal toxicity compared with melphalan and topotecan. Conclusions. Sunitinib may be a “universal” drug for all subtypes of RB. With high efficacy and low retinal toxicity, sunitinib is potential agent used in local chemotherapy for treating RB.

2023-02-08 | GSE201740 | GEO

Sunitinib efficacy with minimal toxicity in patient-derived organoid models of retinoblastoma

Project description:Sunitinib efficacy with minimal toxicity in patient-derived organoid models of retinoblastoma

| PRJNA832801 | ENA

Tissue architecture influences brain organoid identity and developmental trajectory

Project description:Tissue architecture influences brain organoid identity and developmental trajectory

| PRJEB51969 | ENA

Tumor evolution and drug response in patient-derived organoid models of bladder cancer

Project description:Bladder cancer is the fifth most prevalent cancer in the U.S., yet is understudied and relatively lacking in suitable models. Here we describe a biobank of patient-derived organoid lines that recapitulates the spectrum of human bladder cancer at the histopathological and molecular levels. Organoid lines can be established efficiently from patient biopsies, including from patients before and after disease recurrence, and are interconvertible with orthotopic xenografts. Notably, these organoid lines often retain tumor heterogeneity and exhibit changes in their mutational profiles that are consistent with tumor evolution in culture. Analyses of drug response using bladder tumor organoids show partial correlations with mutational profiles as well as changes associated with treatment resistance, and specific responses can be validated using xenografts in vivo. Overall, our studies indicate that patient-derived bladder tumor organoids represent a model system for studying tumor evolution and treatment response in the context of precision cancer medicine.

2018-04-09 | GSE103990 | GEO

Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer

Project description:The purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage IV colorectal cancer.

| 58056 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data